福齐夫定替酯
| 中文名称 | 福齐夫定替酯 |
|---|---|
| 中文同义词 | 福齐夫定替酯;化合物 T27354;化合物 FOZIVUDINE TIDOXIL |
| 英文名称 | Fozivudine |
| 英文同义词 | Fozivudine;fozivudine tidoxil;(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate;BM-211290;FZT;HDP-99.0002;HDP-990002;W-09726867 |
| CAS号 | 141790-23-0 |
| 分子式 | C35H64N5O8PS |
| 分子量 | 745.958 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 141790-23-0.mol |
| 结构式 |  |
福齐夫定替酯 性质
Fozivudine tidoxil (BM-211290) 是具有口服活性的硫醚脂质-齐多夫定 (lipid-zidovudine) 偶联物，具有抗 HIV 活性的。Fozivudine tidoxil 是 NRTI 家族成员，在细胞内病毒复制过程中被掺入到新合成的 DNA 链中，并且不可逆地结合病毒 RT，从而破坏病毒的逆转录。
|
HIV
|
Fozivudine tidoxil (BM-211290) is a member of the nucleoside analogue reverse transcriptase inhibitor (NRTI) family.
Fozivudine tidoxil (BM-211290; 45 mg/kg; PO; twice daily; one day before FIV challenge for a total of six weeks) is effective at lowering plasma- and cell-associated viremia at two weeks post-FIV infection.
| Animal Model: | Specific pathogen-free cats at 6 months of age |
| Dosage: | 45 mg/kg |
| Administration: | PO; twice daily; one day before FIV challenge for a total of six weeks |
| Result: | Effective at lowering plasma- and cell-associated viremia at two weeks post-feline immunodeficiency virus (FIV) infection with a trend toward lower plasma- and cell- associated viremia at four and six weeks post-infection (PI). |